Literature DB >> 11001364

Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice.

S Braun1, C Thioudellet, P Rodriguez, D Ali-Hadji, F Perraud, N Accart, J M Balloul, C Halluard, B Acres, B Cavallini, A Pavirani.   

Abstract

Intramuscular administration of plasmid expressing full-length human dystrophin in dystrophin-deficient adult mdx mice resulted in humoral and weak specific T cell responses against the human dystrophin protein. Following plasmid injection, human dystrophin was detected in the injected muscles at 7 days, but decreased thereafter. Anti-dystrophin antibodies were found 21 days following plasmid injection, which coincided with transient myositis. This immune rejection prevented the mice from expressing human dystrophin after a second plasmid injection. No anti-DNA antibodies were found. Anti-dystrophin antibodies were seen in a smaller proportion of plasmid-injected dystrophin-competent C57BL/10 mice, suggesting that the immune rejection of dystrophin may be explained partially by species differences in the dystrophin protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001364     DOI: 10.1038/sj.gt.3301261

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Ex-vivo analysis of the bone microenvironment in bone metastatic breast cancer.

Authors:  Karen M Bussard; Andrea M Mastro
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-12-02       Impact factor: 2.673

2.  Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections.

Authors:  Erik Depla; Annegret Van der Aa; Brian D Livingston; Claire Crimi; Koen Allosery; Veronique De Brabandere; Jonathan Krakover; Sidharta Murthy; Manley Huang; Scott Power; Lilia Babé; Carol Dahlberg; Denise McKinney; Alessandro Sette; Scott Southwood; Ramilla Philip; Mark J Newman; Lydie Meheus
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 3.  Therapeutics in duchenne muscular dystrophy.

Authors:  Jonathan B Strober
Journal:  NeuroRx       Date:  2006-04

4.  Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin.

Authors:  Christiana DelloRusso; Jeannine M Scott; Dennis Hartigan-O'Connor; Giovanni Salvatori; Catherine Barjot; Ann S Robinson; Robert W Crawford; Susan V Brooks; Jeffrey S Chamberlain
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

5.  Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.

Authors:  Christelle Remy-Ziller; Claire Germain; Anita Spindler; Chantal Hoffmann; Nathalie Silvestre; Ronald Rooke; Jean-Yves Bonnefoy; Xavier Préville
Journal:  Clin Vaccine Immunol       Date:  2013-12-04

6.  Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane.

Authors:  Cosimo De Bari; Francesco Dell'Accio; Frank Vandenabeele; Joris R Vermeesch; Jean-Marc Raymackers; Frank P Luyten
Journal:  J Cell Biol       Date:  2003-03-10       Impact factor: 10.539

7.  Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.

Authors:  Nathalie M Goemans; Már Tulinius; Marleen van den Hauwe; Anna-Karin Kroksmark; Gunnar Buyse; Rosamund J Wilson; Judith C van Deutekom; Sjef J de Kimpe; Afrodite Lourbakos; Giles Campion
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

8.  Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy.

Authors:  Peggy P Ho; Lauren J Lahey; Foteini Mourkioti; Peggy E Kraft; Antonio Filareto; Moritz Brandt; Klas E G Magnusson; Eric E Finn; Jeffrey S Chamberlain; William H Robinson; Helen M Blau; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-04       Impact factor: 12.779

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.